Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update

Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update

May 16, 2016

SER-109 Phase 2 study enrollment complete; results expected in mid-2016

Academic collaborations further microbiome therapeutic leadership in immuno-oncology, rare genetic diseases and other indications

$120 million upfront payment obtained from Nestlé Health Science

 

Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment

Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment

May 12, 2016

- Agreements provide IP license bolstering Company's strong patent portfolio -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a strategic, multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK). The collaboration will support the translation of novel discoveries from MSK laboratories into first-in-field microbiome therapeutics across multiple new cancer indications, where the microbiome may play a critical role.

Editas Medicine Announces First Quarter 2016 Results and Update

Editas Medicine Announces First Quarter 2016 Results and Update

May 16, 2016

Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone

Strengthened effort to develop medicines for cystic fibrosis through agreement with Cystic Fibrosis Foundation Therapeutics .

Robust foundation of intellectual, financial, and human capital positions Editas for long-term success

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

May 16, 2016

Editas to Receive up to $5 Million Award to Fund Genome Editing Research

Evelo Biosciences Participates in White House Office of Science and Technology Policy’s National Microbiome Initiative Event

Evelo Biosciences Participates in White House Office of Science and Technology Policy’s National Microbiome Initiative Event

May 13, 2016

CAMBRIDGE, Mass., May 13, 2016/PRNewswire/-- Evelo Biosciences, the pioneer of Oncobiotic™ Therapies, microbiome-based therapeutics for cancer, is dedicating $1M to award up to 10 grants for joint studies exploring the human microbiome and cancer. Evelo will participate in the National Microbiome Initiative Event, hosted by the White House Office of Science and Technology Policy on Friday, May 13th.

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

February 8, 2016

CAMBRIDGE, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, including 885,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option.

Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease

Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease

May 4, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2016-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced it has entered into two separate research collaborations with leading academic groups to support Seres’ ongoing development of the first potential microbiome therapeutics for inflammatory bowel disease (IBD).

Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics

Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics

May 4, 2016

CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO) for technical progress in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Editas and Juno are pursuing three research programs utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies.

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

May 5, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

Agios Reports First Quarter 2016 Financial Results

Agios Reports First Quarter 2016 Financial Results

May 5, 2016

CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the first quarter ended March 31, 2016.